Frank Reed
Unpacking the breakthroughs that are redefining the limits of human potential.
About This Column
Frank Reed is a strategist and analyst who explores the frontiers of what is possible. Formerly the expert voice behind Precision Future, Frank has expanded his scope to examine the groundbreaking advancements reshaping the human experience. From the ethics of gene editing to the transformative power of artificial intelligence, he specializes in deconstructing the science behind the headlines. His column offers a nuanced understanding of the forces driving the next era of innovation, providing readers with a clear and compelling vision of how technology will revolutionize our world.
Displaying items 481-500 of 512 in total
Decoding Park West's Complex Bet on Qualcomm's Takeover Play
Hedge Fund's Derivative Play in UK Student Housing Mega-Merger
Hedge Funds Bet on Beds: Balyasny’s Move in UK Student Property M&A
Prime Medicine's High-Stakes Pitch for Next-Gen Gene Editing
Driehaus Trims Greencore Stake: Decoding a Key Investor's Move
Weiss Stake in Avadel Fuels Takeover Talk Amid Drug's Success
Hedge Fund Stake in Avadel Highlights Value of Sleep Tech Innovation
Hedge Fund's Hand Revealed in UK Student Property Takeover
Balyasny's Big Bet: Decoding the Play in UK Student Housing
Midwest Fintech Leader Honored for Driving Innovation in Payments Technology
AMR Clinical Charts New Course with Leadership Transition, Eyes Growth in Expanding Trial Market
Healthcare Vets Join Forces with Workforce Tech Firm to Tackle Staffing Crisis
Virginia's Pharma Boom: A New Hub Forges Ahead With $12.5B Investment & Workforce Initiative
U.S. Drug Supply at Risk: Reshoring Efforts Face Cost and Competition Hurdles
Myonex Charts Steady Course with Leadership Transition, Eyes Continued Growth in Complex Trials
Sweat Equity: Data-Driven Hydration Takes Center Stage in Elite Sports
GLP-1 Access Expands as Xevant Launches Lower-Cost Employer Program
Reshoring Rx: Phlow Corp. Pushes for US Pharmaceutical Independence
Weight Loss Claims Under Scrutiny: New Supplement Faces Transparency Questions
